Jul 11, 2025 / 07:00AM GMT
Matts Johansen - Aker Biomarine ASA - Chief Executive Officer
Good morning and welcome to the presentation of Aker BioMarine's highlights and financials for the second-quarter 2025 where, myself, Matts Johansen, the CEO; and the CFO, Katrine Klaveness, will take you through today's presentation. After we are presented, we will host a Q&A session, and you can already now start to send in questions to IR at akerbiomarine.com.
The second quarter now is the ninth quarter in the row where I can stand here and say that we are delivering growth for the company as a whole. We delivered 12% growth over the same quarter last year at $55.3 million and improved the EBITDA 41%, up to $13.6 million EBITDA.
It was driven by good performance in our main two segments, Human Health Ingredients that delivered 15% growth to $29.2 million of revenue and $13.9 million of EBITDA, up 28% from the same quarter last year. Also, Consumer Health Products delivered well in the quarter. $27.1 million of revenue, 9% up compared to the same quarter last year, and $1.6 million of EBITDA.
Emerging Business,
Q2 2025 Aker Biomarine ASA Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
